【摘要】 目的研究多西他赛每周方案联合顺铂二线治疗非小细胞肺癌(NSCLC)的疗效和毒性反应。方法48例晚期非小细胞肺癌患者,既往曾接受1个含铂方案治疗,采用多西他赛30 mg/m2,静脉滴注60 min,第1、8、15 d给药,顺铂40 mg静脉滴注60 min,第1~3 d,每28 d为1周期。患者的行为状态评分(PS)均为ECOG≤2。结果48例患者均可评价,总共化疗周期数为189周期。1例完全缓解(CR)占2.1%,14例部分缓解(PR)占29.2%,有效率(ORR)为31.3%,中位生存时间为37周,1年生存率为33%,粒细胞减少与乏力为主要的毒性反应,其他的毒性反应为脱发和体液潴留。结论多西他赛30 mg/m2每周给药联合顺铂二线治疗NSCLC有确切的疗效且耐受性好。更多还原

【Abstract】 Objective To study the efficacy and safety of docetaxel adiministrated weekly plus cisplatin in treatment of patients with advanced NSCLC.Methods Forty-eight patients with advanced NSCLC were treated by docetaxel at dosage of 30mg/m2 on day 1,8,15 with intravenous infusion for 60 min and cisplatin at a dose of 40mg on days 1~3.This therapeutic regimen was repeated every 28 days.Results The efficacy of treatment could be evaluated in 48 patients,the overall response rate(CR+PR)was 31.3%.One of 48 assessable patients(2.1%) achieved complete response to treatment,14 patients(29.2%) achieved part response to treatment.The median survival time of all patients was 37 weeks,and the 1-year survival rate was 33%.The main acute side effects were fatigue,asthenia and neutropenia,and no other hematologic toxicity was observed.Conclusion Weekly docetaxel therapy is active and well tolerated by patients with advanced NSCLC.更多还原